Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immune response
|
| gptkbp:activatedBy |
gptkb:Bacteria
fungal infection viral infection (indirectly) |
| gptkbp:antigen |
MR1-presented metabolites
|
| gptkbp:decreasedIn |
tuberculosis
HIV infection severe COVID-19 |
| gptkbp:developedBy |
gptkb:thymus
|
| gptkbp:discoveredBy |
Dr. Paul Klenerman
|
| gptkbp:discoveredIn |
2003
|
| gptkbp:expressedIn |
gptkb:CD3
CD161 CD4 (minority) CD8 (majority) T cell receptor (TCR) Vα7.2 in humans |
| gptkbp:foundIn |
gptkb:cancer
blood liver intestine mucosal tissues |
| gptkbp:fullName |
Mucosal-associated invariant T cells
|
| gptkbp:function |
cytotoxicity
cytokine production antimicrobial defense |
| https://www.w3.org/2000/01/rdf-schema#label |
MAIT cells
|
| gptkbp:marking |
gptkb:CD127
gptkb:CD26 gptkb:CD45RO gptkb:CD94 CD161hi Vα7.2+ T cells CD69 |
| gptkbp:prohibits |
MR1 molecule
|
| gptkbp:proportionOfTCells |
1-10% in human blood
up to 40% in human liver |
| gptkbp:recognizedBy |
microbial vitamin B2 (riboflavin) metabolites
|
| gptkbp:relatedTo |
gptkb:gamma-delta_T_cells
gptkb:NKT_cells |
| gptkbp:role |
mucosal immunity
early immune response innate-like immunity |
| gptkbp:secretes |
gptkb:TNF-alpha
gptkb:IFN-gamma IL-17 |
| gptkbp:species |
gptkb:human
gptkb:mouse primate |
| gptkbp:studiedIn |
gptkb:cancer
autoimmune diseases inflammatory bowel disease |
| gptkbp:bfsParent |
gptkb:MR1
|
| gptkbp:bfsLayer |
7
|